Major appetite suppressant
It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by any regulatory authority
(2022) emphasized the need for longitudinal studies to evaluate its metabolic and dermatologic impact, particularly in populations with extended use
The FDA has identified safety concerns with compounded CJC-1295, including serious adverse events such as increased heart rate and systemic vasodilatory reactions
Keywords: L-carnitine, acetyl-carnitine, fatty liver, NAFLD, NASH, cirrhosis, fatty acid transport, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, liver health 1
This case highlights the importance of differentiating mycotoxin illness from CIRS and emphasizes the role of treatment sequencing in complex environmental illness